Danish biopharma giant Novo Nordisk (NOV: N) is breaking new ground with its GLP-1 agonist semaglutide, as a small mid-stage study shows its potential in treating alcohol-use disorder (AUD).
Best known under the brand names Ozempic and Wegovy for diabetes and weight management, the drug was tested against placebo in 48 adults with AUD who were not seeking treatment.
The main finding was that those receiving semaglutide consumed significantly less alcohol during a post-treatment self-administration test, with notable reductions in alcohol craving compared to the placebo group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze